Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development

By sjmartinez • January 24, 2025

Van Naarden JS, Herrmann K, Czernin J. Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development. J Nucl Med. 2025 Jan 23:jnumed.124.269354. doi: 10.2967/jnumed.124.269354. Epub ahead of print. PMID: 39848767.

Tags: Cardiology/Epi, Publications

Adult Congenital Heart Disease Workforce Challenges in the United States: Current State and Future Needs: Proceedings from the American College of Cardiology (ACC), Adult Congenital Pediatric Cardiology (ACPC) Council Adult Congenital Heart Disease Summit

Zaidi AN, Sachdeva R, Kovacs R, Franklin WJ, Gurvitz M, Ermis P, Awerbach JD, Weissman G, Bradley E, Cox D, Daniels CJ, Gregg D 4th,[...]

Longitudinal Data from the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not: JACC Adv. 2025;4(7):101686

Soto-Mota A, Norwitz NG, Manubolu VS, Kinninger A, Wood TR, Earls J, Feldman D, Budoff M. Longitudinal Data from the KETO-CTA Study: Plaque Predicts Plaque,[...]

Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right Atrial Rupture

Makaroff KE, Hampilos K, Sayed S, Emert B, Hu X, Nsair A, Kwon M, Middlekauff H. Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right[...]